Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Slimmed-down THG confident despite revenue fall

(Sharecast News) - THG reported lower revenue and widened losses for 2024, it reported on Tuesday, but maintained a positive outlook after a year of major restructuring. The company, which demerged its technology platform THG Ingenuity last year, said it is now a leaner, more focused group centred on its Beauty and Nutrition divisions.

Revenue for the year ended 31 December fell around 5% year-on-year to £1.75bn, with a pre-tax loss widening to £202.4m from £92.3mi the year before.

Adjusted EBITDA before the demerger was £123.1mi, in line with guidance and market expectations, despite the impact of record-high whey prices pressuring margins in Nutrition.

The Beauty division posted revenue growth of 3.3% at actual exchange rates, reaching £1.108bn, while Nutrition revenues fell 11.9% to £579.8m.

THG said Beauty delivered ahead of its medium-term adjusted EBITDA margin target, helping offset challenges in Nutrition.

In the first quarter of 2025, the group's continuing revenue fell 6.1% at constant currency to £371.4m.

Beauty revenues declined 10% year-on-year, reflecting tough comparisons against a strong prior year period boosted by an early Easter and an additional trading day.

Nutrition returned to modest constant currency growth of 0.1% during the quarter.

Chief executive Matthew Moulding described 2024 as a year of "change and evolution," highlighting the demerger, debt refinancing through to 2029, and THG's entry into the FTSE 250.

He emphasised that the group was now more efficient following operational improvements, including greater use of automation and AI.

Despite ongoing market uncertainty and the potential impact of consumer demand factors later in the year, THG reaffirmed its full-year guidance for mid-single-digit revenue growth in 2025.

The company also said it expected limited exposure to new US tariffs and plans to offset rising employment costs with operational savings.

THG recently rejected a takeover bid for its Myprotein brand from former director Iain McDonald, reinforcing its commitment to its Nutrition operations.

Looking ahead, the group said it was focused on building market share, launching new brands, and maintaining a capital-light model to drive sustainable growth and cash generation.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.